Scholarlink

Background <p>Metabolic associated fatty liver disease (MAFLD) has emerged as the most common chronic liver disease worldwide. However, effective pharmacological treatments remain limited. Dysregulated lipid metabolism and impaired bile acid synthesis are recognized as key contributors to the pathogenesis of MAFLD. This study aimed to investigate the therapeutic potential and underlying mechanisms of nitroxoline (Nit), an antimicrobial agent identified through drug repurposing, in ameliorating hepatic steatosis.</p> Methods <p>Nit was administered to high-fat diet (HFD)-fed low-density lipoprotein receptor knockout (<i>Ldlr</i><sup>⁻/⁻</sup>) mice to assess hepatic steatosis, aortic atherosclerosis, serum lipid levels, and bile acid metabolism comprehensively. In vitro, Huh-7 cells were used to examine Nit-mediated regulation of lipid metabolism-related genes. RNA sequencing (RNA-seq) and pharmacologic inhibition studies were conducted to elucidate the underlying molecular mechanisms.</p> Results <p>Nit treatment significantly reduced liver weight without affecting body weight in HFD-fed <i>Ldlr⁻/⁻</i> mice. Serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglyceride levels were markedly decreased. Mechanistically, Nit enhanced the expression of ATP-binding cassette subfamily G5 (ABCG5) and G8 (ABCG8) transporters, along with cholesterol 7α-hydroxylase (CYP7A1), thereby promoting cholesterol efflux into bile and bile acid synthesis. In Huh-7 cells, Nit induced ABCG5, ABCG8 and CYP7A1 expression in a dose-dependent manner. Furthermore, RNA-Seq analysis revealed liver receptor homolog-1 (LRH-1) as a potential transcriptional regulator related to Nit. Notably, pretreatment with the LRH-1 inhibitor, ML-180 abolished Nit-induced upregulation of ABCG5, ABCG8 and CYP7A1, suggesting that Nit may alleviate hepatic lipid accumulation primarily through LRH-1 activation.</p> Conclusions <p>This study identifies Nit as a promising pharmacological candidate for MAFLD by modulating cholesterol metabolism and bile acid synthesis through LRH-1-mediated activation. These findings not only advance the understanding of metabolic liver disease pathogenesis but also support the development of innovative and accessible therapeutic strategies by leveraging existing compounds to improve health outcomes.</p> Graphical Abstract <p>Schematic summary of the anti-steatotic effects of Nit. In HFD-fed <i>Ldlr</i><sup><i>⁻/⁻</i></sup> mice, Nit treatment attenuated dyslipidemia, lowered serum total cholesterol, triglycerides, and LDL-C levels, and reduced hepatic lipid accumulation. In both mice liver and Huh-7 cell, Nit upregulated LRH-1, which activated ABCG5, ABCG8, as well as CYP7A1, thereby enhancing cholesterol efflux and bile acid synthesis. These effects highlighted LRH-1 as a central mediator of Nit-induced lipid homeostasis.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nitroxoline mitigates hepatic steatosis by enhancing cholesterol efflux and promoting bile acid synthesis through LRH-1 signaling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Wen-Cheng Liu,
  • Chih-Feng Lien,
  • Yi-Jhen Huang,
  • Pei-Yu Lien,
  • Sy-Jou Chen,
  • Chin-Sheng Lin,
  • Rou-Ling Cho,
  • Yi-Ping Chuang

摘要

Background

Metabolic associated fatty liver disease (MAFLD) has emerged as the most common chronic liver disease worldwide. However, effective pharmacological treatments remain limited. Dysregulated lipid metabolism and impaired bile acid synthesis are recognized as key contributors to the pathogenesis of MAFLD. This study aimed to investigate the therapeutic potential and underlying mechanisms of nitroxoline (Nit), an antimicrobial agent identified through drug repurposing, in ameliorating hepatic steatosis.

Methods

Nit was administered to high-fat diet (HFD)-fed low-density lipoprotein receptor knockout (Ldlr⁻/⁻) mice to assess hepatic steatosis, aortic atherosclerosis, serum lipid levels, and bile acid metabolism comprehensively. In vitro, Huh-7 cells were used to examine Nit-mediated regulation of lipid metabolism-related genes. RNA sequencing (RNA-seq) and pharmacologic inhibition studies were conducted to elucidate the underlying molecular mechanisms.

Results

Nit treatment significantly reduced liver weight without affecting body weight in HFD-fed Ldlr⁻/⁻ mice. Serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglyceride levels were markedly decreased. Mechanistically, Nit enhanced the expression of ATP-binding cassette subfamily G5 (ABCG5) and G8 (ABCG8) transporters, along with cholesterol 7α-hydroxylase (CYP7A1), thereby promoting cholesterol efflux into bile and bile acid synthesis. In Huh-7 cells, Nit induced ABCG5, ABCG8 and CYP7A1 expression in a dose-dependent manner. Furthermore, RNA-Seq analysis revealed liver receptor homolog-1 (LRH-1) as a potential transcriptional regulator related to Nit. Notably, pretreatment with the LRH-1 inhibitor, ML-180 abolished Nit-induced upregulation of ABCG5, ABCG8 and CYP7A1, suggesting that Nit may alleviate hepatic lipid accumulation primarily through LRH-1 activation.

Conclusions

This study identifies Nit as a promising pharmacological candidate for MAFLD by modulating cholesterol metabolism and bile acid synthesis through LRH-1-mediated activation. These findings not only advance the understanding of metabolic liver disease pathogenesis but also support the development of innovative and accessible therapeutic strategies by leveraging existing compounds to improve health outcomes.

Graphical Abstract

Schematic summary of the anti-steatotic effects of Nit. In HFD-fed Ldlr⁻/⁻ mice, Nit treatment attenuated dyslipidemia, lowered serum total cholesterol, triglycerides, and LDL-C levels, and reduced hepatic lipid accumulation. In both mice liver and Huh-7 cell, Nit upregulated LRH-1, which activated ABCG5, ABCG8, as well as CYP7A1, thereby enhancing cholesterol efflux and bile acid synthesis. These effects highlighted LRH-1 as a central mediator of Nit-induced lipid homeostasis.